Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe

Abstract Background Renal cell carcinoma (RCC) was historically considered to be less responsive to radiation therapy (RT) compared to other cancer indications. However, advancements in precision high-dose radiation delivery through single-fraction and multi-fraction stereotactic ablative radiothera...

詳細記述

書誌詳細

出版年:	Journal of Experimental & Clinical Cancer Research
主要な著者:	Hari K. Rachamala, Vijay S. Madamsetty, Ramcharan S. Angom, Naga M. Nakka, Shamit Kumar Dutta, Enfeng Wang, Debabrata Mukhopadhyay, Krishnendu Pal
フォーマット:	論文
言語:	英語
出版事項:	BMC 2024-06-01
主題:	Renal cancer Radiation therapy mTOR Survivin Mitotic catastrophe
オンライン･アクセス:	https://doi.org/10.1186/s13046-024-03079-8